Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions

Evaluating the Effect of Desflurane Versus Sevoflurane With Recent Biomarkers of Renal and Hepatic Function in Laparoscopic Cholecystectomy Patients: A Prospective Randomized Double Blinded Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05027191

Enrollment

Registered

2021-08-30

Start date

2018-02-15

Completion date

2019-12-01

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications

Brief summary

Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

Interventions

DIAGNOSTIC_TESTNeutrophil Gelatinase-Associated Lipocalin (NGAL)

The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.

DRUGDesflurane

Desflurane

DRUGSevoflurane

Sevoflurane

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 55 Years

Healthy volunteers

Inclusion criteria

1. American Society of Anesthesiologists (ASA) Class: I&II. 2. Elective laparoscopic cholecystectomy. 3. Age: 25-55 years. 4. Gender: Both male and female. 5. Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).

Exclusion criteria

1. Extremes of age. 2. Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range. 3. Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges. 4. Hypertension, unstable angina pectoris or myocardial infarction within the last six months. 5. Pregnancy and lactation. 6. Bronchial asthma. 7. Drug allergies. 8. Alcohol or drug addiction. 9. General anesthesia within the last three months.

Design outcomes

Primary

Measure	Time frame	Description
Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)	a change from baseline NGAL serum level at 6 hours	Renal Biomarker

Secondary

Measure	Time frame	Description
Change in urine Netrin-1	Baseline, first hour, six hours, after 24 hours	Renal biomarker
Change in urine Kidney Injury Molecule	Baseline, first hour, six hours, after 24 hours	Renal biomarker
Change in serum Cystatin-c	Baseline, first hour, six hours, after 24 hours	Hepatic biomarker
Change in urine Alpha-Glutathione S-Transferase	Baseline, first hour, six hours, after 24 hours	Liver biomarker
Change in serum Arginase	Baseline, first hour, six hours, after 24 hours	Hepatic biomarker
Change in urine Interleukin-18	Baseline, first hour, six hours, after 24 hours	cytokines

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026